Healthcare providers worldwide face the same key challenge – a challenge that ContextVision is helping to solve: how to increase patient care while coping with limited resources. ContextVision provides intelligent technology that improves healthcare service and outcomes for more people.
The company specializes in image analysis and artificial intelligence, and is leading research into the application of deep learning, the latest machine learning technology.
As an industry pioneer for more than 30 years, ContextVision is the global market leader in image enhancement. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company’s product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography, which is used by leading equipment manufacturers worldwide.
ContextVision is currently investing significantly to expand its product portfolio and to expand into a new rapidly growing market, digital pathology. ContextVision is assuming a leading position in the image analysis and decision support markets, and the company is continues its aggressive research and development program to develop unique products that serve the needs of healthcare and the healthcare Industry.
ContextVision is based in Sweden, and has local representation in the U.S., Japan, China and Korea. The company is listed on the Oslo Stock Exchange under the ticker COV.
ContextVision was established in 1983 by a specialist research team at Linköping University in Sweden. The university has been a center for digital image analysis with a history of spearheading research in the field since the 1970s.
ContextVision’s major breakthrough within the medical field came in 1987 when the company signed its first original equipment manufacturer (OEM) agreement. Since then, its powerful medical image enhancement software for MRI, X-ray and ultrasound have continued to set new standards and lead the market. In 2009, ContextVision again pioneered the market by launching the first filter for 3D to enhance 3D/4D ultrasound images.
Recently, the company has developed expertise within artificial intelligence and the latest machine learning technology, deep learning. In October 2016, the company scored second in an international competition, using deep learning for image analysis, and thereby was internationally acknowledged for its knowledge of the technology.
ContextVision is also supporting a new digital pathology research program, which is sponsored by Eurostars and which was begun in 2015, with the aim of developing innovative decision support products within various cancer types, including prostate cancer and breast cancer.